Recurrent neutropenia due to dopamine agonists in a patient with microprolactinoma.
The objective of our case report is to increase the awareness of neutropenia as a rare but potentially serious adverse outcome of commonly used dopamine agonists for the treatment of prolactinomas. This report reviews the clinical history, diagnosis, investigations, and drug treatment of our patient. Neutropenia was recurrent after changing to various different dopamine agonists necessitating surgical treatment of a prolactinoma. This case serves a reminder of this adverse drug reaction. Considering the significant impact and potentially a life threatening outcome, we advocate routine monitoring of full blood count prior to and during the treatment with dopamine agonists.